Edition:
United Kingdom

Celgene Says FDA Approves Otezla (Apremilast) For Treatment Of Oral Ulcers Associated With Behçet’s Disease


Friday, 19 Jul 2019 

July 19 (Reuters) - Celgene Corp ::FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ORAL ULCERS ASSOCIATED WITH BEHÇET’S DISEASE.CELGENE CORP - FDA APPROVAL WAS BASED ON EFFICACY AND SAFETY RESULTS FROM RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 3 RELIEF STUDY.CELGENE CORP - U.S. FDA APPROVED OTEZLA 30 MG TWICE DAILY (BID) FOR TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHÇET'S DISEASE.CELGENE - SEES REGULATORY DECISION FOR OTEZLA IN ORAL ULCERS ASSOCIATED WITH BEHÇET'S DISEASE FROM PHARMACEUTICALS & MEDICAL DEVICES AGENCY IN JAPAN IN H2 2019.